Abbott 3Q Revenues: $5.6 billion (+3.5%) 3Q Earnings: $715.8 million (+5%) YTD Revenues: $16.3 billion (flat) YTD Earnings: $2.2 billion (-8.5%) Comments: Adjusting for the Boehringer Ingelheim (BI) distribution amendment, U.S. pharmaceutical sales increased nearly 17%, driven by Humira, Omnicef, Depakote, Kaletra and TriCor.* Global Humira sales were $541 million, up 52%, with U.S. sales up 43% and international sales up 66%. Results for the quarter include acquired in-proce...